Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute)(Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute)) - 药物靶点：CD7_在研适应症：急性髓性白血病，CD7阳性血液肿瘤，CD7阳性肿瘤_专利_临床

概要

基本信息

药物类型

通用型CAR-T

别名

4SCAR7U

靶点

CD7

作用机制

CD7调节剂(T细胞抗原CD7调节剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [1]

在研适应症

急性髓性白血病CD7阳性血液肿瘤CD7阳性肿瘤+ [3]

非在研适应症-

原研机构

Shenzhen Geno-Immune Medical Institute

在研机构

Shenzhen Geno-Immune Medical Institute

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

关联

2

项与 Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute) 相关的临床试验

NCT05995028 / Recruiting临床1期IIT

Safety and Efficacy of Universal 4SCAR7U T Cell Therapy Targeting CD7-positive Hematological Malignancies

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hematological malignancies using CD7 specific universal CAR T cells. The study also aims to learn more about the function of CD7 targeting CAR T cells and their persistence in patients of hematological malignancies.

开始日期2023-10-31

申办/合作机构

Shenzhen Geno-Immune Medical Institute

NCT04033302 / Unknown status临床1/2期IIT

A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of CAR T cell therapy against CD7-positive hematological malignancies using CD7 specific CAR T cells. The study also aims to learn more about the function of CD7 CAR T cells and their persistence in patients of hematological malignancies.

开始日期2019-09-01

申办/合作机构

Shenzhen Geno-Immune Medical Institute

100 项与 Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute) 相关的临床结果

登录后查看更多信息

100 项与 Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute) 相关的转化医学

登录后查看更多信息

100 项与 Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Universal CD7-specific CAR gene-engineered T cells(Shenzhen Geno-Immune Medical Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	临床1期	中国	Shenzhen Geno-Immune Medical Institute	2023-10-31
CD7阳性血液肿瘤	临床1期	中国	Shenzhen Geno-Immune Medical Institute	2023-10-31
CD7阳性肿瘤	临床1期	中国	Shenzhen Geno-Immune Medical Institute	2023-10-31
NK细胞淋巴瘤	临床1期	中国	Shenzhen Geno-Immune Medical Institute	2023-10-31
前体T淋巴细胞白血病淋巴瘤	临床1期	中国	Shenzhen Geno-Immune Medical Institute	2023-10-31
T细胞急性淋巴细胞白血病/淋巴瘤	临床1期	中国	Shenzhen Geno-Immune Medical Institute	2023-10-31